Source:http://linkedlifedata.com/resource/pubmed/id/10678366
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2000-2-29
|
pubmed:abstractText |
The onco-suppressor gene TP53 has potential use in the gene therapy of many human cancers including leukemias. The latter indication derived from numerous experimental reports of p53-mediated suppressing effects on human and murine leukemia cells in vitro. However, few in vivo experiments have been performed, and those that have used a subcutaneous injection of p53-transduced leukemia cells. Thus, we developed an orthotopic leukemia model in adult, syngenic mice to evaluate the feasibility of TP53-mediated therapeutic approaches. We found that among other cells, v-src-transformed 32D myeloid progenitors induce leukemia when injected intravenously in syngenic mice. The resulting malignancy resembles the clinical manifestations of human acute myeloid leukemia because it is characterized by a massive invasion of bone marrow compartments, splenomegaly, generalized lymphadenopathy, and a macroscopic or microscopic infiltration of the kidneys, liver, and lungs. When these 32Dv-src cells were infected with a TP53-recombinant retrovirus before intravenous injection, we found a decreased mortality and, in those animals that develop leukemia, a drastic reduction of the generalized organ infiltration, suggesting that exogenous TP53 expression might be used for ex vivo bone marrow purging from leukemia cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0929-1903
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
135-43
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10678366-Animals,
pubmed-meshheading:10678366-Disease Models, Animal,
pubmed-meshheading:10678366-Feasibility Studies,
pubmed-meshheading:10678366-Gene Therapy,
pubmed-meshheading:10678366-Genetic Vectors,
pubmed-meshheading:10678366-Leukemia,
pubmed-meshheading:10678366-Male,
pubmed-meshheading:10678366-Mice,
pubmed-meshheading:10678366-Mice, Inbred C3H,
pubmed-meshheading:10678366-Neoplasm Transplantation,
pubmed-meshheading:10678366-Retroviridae,
pubmed-meshheading:10678366-Tumor Suppressor Protein p53
|
pubmed:year |
2000
|
pubmed:articleTitle |
Development of a murine orthotopic model of leukemia: evaluation of TP53 gene therapy efficacy.
|
pubmed:affiliation |
Molecular Oncogenesis Laboratory, Regina Elena Cancer Institute--Centro Richerche Sperimentali, Rome, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|